Literature DB >> 29169190

Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer.

Stephanie Allelein1, Margret Ehlers1, Corinna Morneau1, Katharina Schwartz2, Peter E Goretzki2, Thomas Seppel3, Joachim Feldkamp4, Andreas Krieg5, Wolfram Trudo Knoefel5, Anne Kuebart1, Matthias Haase1, Till Dringenberg1, Christine Schmid1, Matthias Schott1.   

Abstract

Calcitonin (CT), a tumor marker for medullary thyroid cancer (MTC), can be stimulated with pentagastrin or calcium. Because of the unavailability of pentagastrin, basal CT measurement is frequently used for the preoperative diagnosis of MTC. The aim of the study was to define basal serum calcitonin (bCT) cut-off thresholds for diagnosing MTC. Within a retrospective analysis, 114 patients (51 males) were included fulfilling the criteria of an increased preoperative bCT level (>10 pg/ml) and the criteria of an available postoperative histology analysis. Based on a ROC plot analysis, the cut-off values for the diagnosis of MTC vs. non-malignancy (C cell hyperplasia and goiter) were identified. The most precise bCT thresholds for the identification of MTC were ≥46 pg/ml for males (sensitivity: 93.6%, specificity: 95.0%, PPV: 97%, NPV: 90%) and ≥35 pg/ml for females (sensitivity: 87.3%, specificity: 87.5%, PPV: 98%, NPV: 50%). Using these cut-offs, only 6% of male patients were not identified of having MTC, whereas 5% were false positive (having instead C cell hyperplasia). In females, the discrepancy was higher since 13% of female MTC patients were false negative by using the cut-off of ≥35 pg/ml, and 13% had false positive results (suffering from C cell hyperplasia). Gender-specific bCT cut-offs for the identification of MTC vs. C cell hyperplasia and non-malignancy were defined, which can be used in clinical routine. In female patients, however, the accuracy is much lower compared to males. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29169190     DOI: 10.1055/s-0043-122237

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  8 in total

1.  Editorial : Neuroendocrine neoplasms.

Authors:  Christian A Koch; Stephan Petersenn
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

2.  Calcitonin Screening in Nodular Goiter-Upper Limits.

Authors:  Friedhelm Raue; Karin Frank-Raue
Journal:  Dtsch Arztebl Int       Date:  2018-03-30       Impact factor: 5.594

3.  In Reply.

Authors:  Detlef K Bartsch; Markus Luster; Peter E Goretzki
Journal:  Dtsch Arztebl Int       Date:  2018-03-30       Impact factor: 5.594

4.  Diagnostic accuracy of routine calcitonin measurement for the detection of medullary thyroid carcinoma in the management of patients with nodular thyroid disease: a meta-analysis.

Authors:  Irfan Vardarli; Manuel Weber; Frank Weidemann; Dagmar Führer; Ken Herrmann; Rainer Görges
Journal:  Endocr Connect       Date:  2021-03       Impact factor: 3.335

5.  Does pretreatment elevated calcitonin level cause the poor prognosis in patients with medullary thyroid cancer?

Authors:  Han Zhang; Daqi Zhang; Chengqiu Sui; Jingting Li; Canxiao Li; Qiao He; Rui Du; Yishen Zhao; Yantao Fu; Le Zhou; Tie Wang; Gianlorenzo Dionigi; Nan Liang; Hui Sun
Journal:  Ann Transl Med       Date:  2022-06

6.  Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma.

Authors:  Arezou A Ghazani; Katelyn M Breen; Meaghan Dwan; Justine A Barletta; Donna R Vatnick; Samantha M Stokes; Caroline Block; Gerard M Doherty; Aviva Y Cohn; Ellen Marqusee; Judy E Garber; Huma Q Rana
Journal:  Am J Case Rep       Date:  2020-12-27

7.  Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: updated thresholds and safety assessment.

Authors:  L Fugazzola; M Di Stefano; S Censi; A Repaci; C Colombo; F Grimaldi; F Magri; U Pagotto; M Iacobone; L Persani; C Mian
Journal:  J Endocrinol Invest       Date:  2020-07-12       Impact factor: 4.256

8.  The value of routine measurement of serum calcitonin on insufficient, indeterminate, and suspicious thyroid nodule cytology.

Authors:  Muhammed Erkam Sencar; Sema Hepsen; Murat Çalapkulu; Hayri Bostan; Davut Sakiz; Ilknur Ozturk Unsal; Hakan Duger; Muhammed Kizilgul; Bekir Ucan; Tugba Taskin Turkmenoglu; Mustafa Ozbek; Erman Cakal
Journal:  Bosn J Basic Med Sci       Date:  2022-02-01       Impact factor: 3.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.